Effects of acute administration of beraprost sodium on parameters related to atherosclerotic vascular damage in coronary artery disease

Journal of Cardiology

Volumn 43, Issue 2, 2004, Pages 53-58

  Tomiyama, Hirofumi ^a   Arai, Tomio ^a   Hirose, Ken Ichi ^a   Koji, Yutaka ^a   Motobe, Kohki ^a   Yambe, Minoru ^a   Yamashina, Akira ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Coronary artery disease; Endothelium; Platelets; Prostacyclin

Indexed keywords

ANGIOTENSIN ANTAGONIST; BERAPROST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA THROMBOGLOBULIN; CALCIUM ANTAGONIST; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRATE; PADGEM PROTEIN; PROSTACYCLIN DERIVATIVE; VASCULAR CELL ADHESION MOLECULE 1; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; PROSTACYCLIN;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD FLOW VELOCITY; BLOOD VESSEL INJURY; CLINICAL ARTICLE; COLD PRESSOR TEST; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; FOREARM BLOOD FLOW; HUMAN; HYPEREMIA; HYPERTENSION; MALE; PULSE WAVE; THROMBOCYTE ACTIVATION; ARTERIOSCLEROSIS; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PULSE RATE; VASCULAR ENDOTHELIUM;

AGED; ANTI-INFLAMMATORY AGENTS; ARTERIOSCLEROSIS; BETA-THROMBOGLOBULIN; CORONARY ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; FEMALE; HUMANS; MALE; MIDDLE AGED; PULSE; VASCULAR CELL ADHESION MOLECULE-1;

EID: 2142772564     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Libby P: Inflammation in atherosclerosis. Nature 2002; 420: 868-874
2. Krieglstein CF, Granger DN: Adhesion molecules and their role in vascular disease. Am J Hypertens 2001; 14: 44S-54S
3. Black PH, Garbutt LD: Stress, inflammation and cardiovascular disease. J Psychosom Res 2002; 52: 1-23
4. Buemi M, Allegra A, Aloisi C, Corica F, Alonci A, Ruello A, Montalto G, Frisina N: Cold presser test raises serum concentrations of ICAM-1, VCAM-1, and E-selectin in normotensive and hypertensive patients. Hypertension 1997; 30: 845-847
5. Bonetti PO, Lerman LO, Lerman A: Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-175
6. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, Koji Y, Hori S, Yamamoto Y: Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359-364
7. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG: Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: An integrated index of vascular function? Circulation 2002; 106: 2085-2090
8. Dormandy JA: Prostanoid drug therapy for peripheral arterial occlusive disease: The European experience. Vasc Med 1996; 1: 155-158
9. Lievre M, Morand S, Besse B, Fiessinger JN, Boissel JP, for the Beraprost et Claudication Intermittente (BERCI) Research Group: Oral beraprost sodium, a prostaglandin I (2)analogue, for intermittent claudication: A double-blind, randomized, multicenter controlled trial. Circulation 2000; 102: 426-431
10. Higashi Y, Sasaki S, Nakagawa K, Ueda T, Yoshimizu A, Kurisu S, Matsuura H, Kajiyama G, Oshima T: A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: A multicenter study. J Am Coll Cardiol 2000; 35: 284-291
11. Hannson GK: Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890
12. Galen FX: Cell adhesion molecules in hypertension: Endothelial markers of vascular injury and predictors of target organ damage? J Hypertens 2002; 20: 813-816
13. Ruggeri ZM: Platelets in atherothrombosis. Nat Med 2002; 8: 1227-1234
14. Rand ML, Leung R, Packham MA: Platelet function assays. Transfus Apheresis Sci 2003; 28: 307-317
15. Ridker PM, Buring JE, Rifai N: Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-495
16. Kiowski W: Endothelial dysfunction in hypertension. Clin Exp Hypertens 1999; 21: 635-646
17. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Rand WM, Udelson JE, Karas RH: Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol 2001; 38: 1843-1849
18. Shaw JA, Chin-Dusting JP, Kingwell BA, Dart AM: Diurnal variation in endothelium-dependent vasodilatation is not apparent in coronary artery disease. Circulation 2001; 103: 806-812
19. Knudtson ML, Flintoft VF, Roth DL, Hansen JL, Duff HJ: Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1990; 15: 691-697
20. Hoffmann R, Mintz GS: Coronary in-stent restenosis: Predictors, treatment and prevention. Eur Heart J 2000; 21: 1739-1749
21. Costanzo A, Moretti F, Burgio VL, Bravi C, Guido F, Levrero M, Puri PL: Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase(NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 2003; 195: 402-410